UCB Research

UCB is a global biopharmaceutical company headquartered in Brussels, Belgium, that focuses on the discovery and development of innovative medicines for people living with severe diseases in immunology and neurology. The company maintains a robust portfolio of commercial products, including blockbuster treatments for epilepsy and recently launched biologics for autoimmune conditions. UCB integrates advanced research in monoclonal antibodies and small molecules with emerging capabilities in gene therapy to address high unmet medical needs. With a presence in approximately 40 countries, the company is recognized for its patient-centric approach and significant investment in research and development.